{
    "clinical_study": {
        "@rank": "30056", 
        "arm_group": [
            {
                "arm_group_label": "FID 119515A", 
                "arm_group_type": "Experimental", 
                "description": "1 drop in the study eye, single dose"
            }, 
            {
                "arm_group_label": "BLINK TEARS", 
                "arm_group_type": "Active Comparator", 
                "description": "1 drop in the study eye, single dose"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the effect of FID 119515A to Blink\u00ae  Tears on the\n      integrity of tear film in adults with a history of dry eye in both eyes."
        }, 
        "brief_title": "Efficacy and Safety Study of FID 119515A", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Dry Eye", 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects who meet the enrollment criteria will be randomized in a 2:1 manner to receive\n      treatment with FID 119515A or Blink Tears respectively for this one-day, single-dose study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Sign Informed Consent.\n\n          -  At least a 3 month documented history of dry eye in both eyes.\n\n          -  Tear break-up time and Ocular Surface Disease Index Questionnaire score as specified\n             in protocol.\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Pregnant or breastfeeding.\n\n          -  Any evidence of ocular infection or inflammation within 30 days prior to Screening.\n\n          -  Any ocular surgery.\n\n          -  Ocular trauma requiring medical or pharmacological treatment within 1 year of\n             Screening.\n\n          -  Current presence of punctal plugs (permanent or temporary) or previous permanent\n             punctal closure by cautery/diathermy.\n\n          -  Use of topical ocular prescription or non-prescription medications within 30 days of\n             Screening.\n\n          -  Participation in any other clinical trial within 30 days prior to Screening.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01833117", 
            "org_study_id": "C-12-021"
        }, 
        "intervention": [
            {
                "arm_group_label": "FID 119515A", 
                "intervention_name": "FID 119515A topical ocular drops", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "BLINK TEARS", 
                "intervention_name": "BLINK TEARS topical ocular drops", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Dry eye", 
            "Tear film", 
            "Tear break-up time", 
            "Ocular surface", 
            "Eye drops"
        ], 
        "lastchanged_date": "June 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center at 1-888-451-3937 for Trial Locations"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Observer-Masked, Efficacy and Safety Study of FID 119515A in Dry Eye", 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Lisa Lindsey, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Fluorescein dye is instilled in the eye to assess tear break-up time. Tear break-up time will be assessed prior to test article instillation (baseline) and at 60 minutes post test article instillation.", 
            "measure": "Mean change from baseline in tear break-up time (TBUT) at 60 minutes", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 60 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01833117"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Fluorescein dye is instilled in the eye to assess tear break-up time. Tear break-up time will be assessed prior to test article instillation (0 minutes) and at intervals up to 60 minutes post test article instillation.", 
            "measure": "Area under curve (AUC) of TBUT from 0 to 60 minutes", 
            "safety_issue": "No", 
            "time_frame": "0 to 60 minutes"
        }, 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}